<DOC>
	<DOCNO>NCT02789384</DOCNO>
	<brief_summary>This prospective observational biomarker study include patient non-metastatic , soft-tissue sarcoma ( STS ) neoadjuvant chemotherapy consider best option multidisciplinary sarcoma team one participating center .</brief_summary>
	<brief_title>CINSARC Signature Correlation With Hemotherapy Efficacy Soft-tissue Sarcomas . A Biomarker Study .</brief_title>
	<detailed_description>Even retrospective statistical identification biomarker achieve , ultimate proof usefulness clinic still require prospective evidence . Our prospective study aim validate prognosis value CINSARC signature prospective way . Moreover , neoadjuvant set ideal one identify molecular predictive factor sensitivity chemotherapy correlate tumor response genetic profile STS . Moreover , molecular profile treatment-refractory tumor cell may reveal alteration associate drug resistance , metastatic recurrence disease progression . The identification factor neoadjuvant setting may help improve management STS patient adjuvant metastatic setting</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>1 . Histologically confirm softtissue sarcoma central review , except diagnosis already confirm RRePS ( Réseau de Référence en Pathologie de Sarcomes et de Viscères ) Network , 2 . Available archived frozen tumor tissue sample patient consent undergo biopsy tumour research purpose , 3 . Nonmetastatic disease , use chemotherapy `` downstage '' sarcoma prior surgery , assume result well local tumor control multidisciplinary sarcoma team one French reference center involve study , 4 . Age ≥ 18 year , 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 1 , 6 . Measurable disease accord RECIST v1.1 outside previously irradiated field , 7 . Neoadjuvant anthracyclinebased chemotherapy propose best option multidisciplinary sarcoma team one French reference center involve study , 8 . No prior concurrent malignant disease diagnose treat last 2 year except adequately treat situ carcinoma cervix , basal squamous skin cell carcinoma , situ transitional bladder cell carcinoma , 9 . Voluntarily sign date write informed consent prior study specific procedure , 10 . Patients social security compliance French Law relate biomedical research ( Article 112111 French Public Health Code ) . 1 . Pathological diagnosis different softtissue sarcoma , 2 . Histological subtypes : welldifferentiated liposarcoma , alveolar softpart sarcoma , dermatofibrosarcoma protuberans , clearcell sarcoma , rhabdomyosarcoma , 3 . Previous treatment sarcoma , 4 . Contraindication preclude administration chemotherapy assess investigator , 5 . Participation study involve medical therapeutic intervention last 30 day , 6 . Previous enrolment present study , 7 . Pregnant breast feed woman , 8 . Patient unable follow comply study procedure geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>soft-tissue sarcoma</keyword>
	<keyword>CINSARC</keyword>
	<keyword>biomarker</keyword>
	<keyword>efficacy</keyword>
	<keyword>pronostic</keyword>
</DOC>